Lucid Diagnostics (LUCD) Q2 FY26 earnings call

Lucid Diagnostics reported Q2 FY26 revenue of $1.5 million, up 17% sequentially, driven by increased commercial focus despite flat test volumes. The company achieved a significant milestone by securing its first LBM coverage policy from Concert, covering nearly 10 million lives, and is making strong progress with VA contracts and health system engagements. While awaiting Medicare draft LCD publication, management remains confident in a positive outcome and is actively building commercial infrastructure to capitalize on broader reimbursement.